20s Proteasome - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

20s Proteasome - Pipeline Review, H1 2016

Summary

Global Markets Direct's, '20s Proteasome - Pipeline Review, H1 2016', provides in depth analysis on 20s Proteasome targeted pipeline therapeutics. 

The report provides comprehensive information on the 20s Proteasome , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 20s Proteasome targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for 20s Proteasome 
- The report reviews 20s Proteasome targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in 20s Proteasome targeted therapeutics and enlists all their major and minor projects 
- The report assesses 20s Proteasome targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to 20s Proteasome targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for 20s Proteasome 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding 20s Proteasome development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
20s Proteasome Overview 6
Therapeutics Development 7
20s Proteasome - Products under Development by Stage of Development 7
20s Proteasome - Products under Development by Therapy Area 8
20s Proteasome - Products under Development by Indication 9
20s Proteasome - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
20s Proteasome - Products under Development by Companies 13
20s Proteasome - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
20s Proteasome - Companies Involved in Therapeutics Development 21
Amgen Inc. 21
LG Life Science LTD. 23
20s Proteasome - Drug Profiles 24
carfilzomib - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
marizomib - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
oprozomib - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Small Molecules to Inhibit 20S Proteasome for Multiple Myeloma and Solid Tumor - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
VPE-001 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
VPEA-002 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
VPEA-004 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
VR-23 - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
20s Proteasome - Dormant Projects 47
20s Proteasome - Featured News & Press Releases 48
Jun 10, 2016: New Analyses From Pivotal Phase 3 Studies Show Kyprolis (Carfilzomib) Allows Patients With Relapsed Multiple Myeloma To Live Longer Without Disease Progression 48
Jun 09, 2016: Preliminary data for pre-kidney transplant being presented June 13 52
Jun 06, 2016: New Phase 3 Secondary Analysis Shows Progression-Free Survival Benefit In Early Relapsing Multiple Myeloma Patients Treated With Kyprolis (Carfilzomib)-Based Regimen 53
Jun 04, 2016: Triphase Accelerator Corporation Announces Positive Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma 54
Jun 03, 2016: Amgen Announces Launch Of KYPROLIS (carfilzomib) CENTRAL, An Online News Resource Demonstrating The Impact Of Relapsed Multiple Myeloma On The Lives Of Patients And Caregivers 55
May 27, 2016: Amgen Receives Positive CHMP Opinion To Extend Indication Of Kyprolis (Carfilzomib) For The Treatment Of Relapsed Multiple Myeloma 55
May 26, 2016: Kyprolis (Carfilzomib) Demonstrates Economic Value In Relapsed Or Refractory Multiple Myeloma Manuscript Published In "Journal of Medical Economics" 56
May 19, 2016: Amgen Highlights Data on Kyprolis at 21st Congress Of The European Hematology Association 57
May 18, 2016: Amgen To Present Data on Kyprolis (carfilzomib) At ASCO 2016 59
Apr 19, 2016: Triphase Accelerator Corporation Announces Positive Interim Results of Phase 1 Trial of Marizomib and Bevacizumab in Malignant Glioma 60
Feb 12, 2016: New Drug Treatment Kyprolis (carfilzomib) for Relapsed Multiple Myeloma Launches in the UK 60
Jan 21, 2016: FDA Approves New Kyprolis (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma 62
Dec 08, 2015: Triphase Accelerator to Present Marizomib Clinical and Preclinical Data at Annual Meeting of the American Society of Hematology 64
Dec 05, 2015: Amgen Submits Application In Europe To Expand Indication Of Kyprolis (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma 65
Dec 05, 2015: New Analyses Presented At ASH 2015 Demonstrate The Potential Of Kyprolis (Carfilzomib) As Backbone Therapy In Multiple Myeloma 66
Appendix 69
Methodology 69
Coverage 69
Secondary Research 69
Primary Research 69
Expert Panel Validation 69
Contact Us 69
Disclaimer 70

List of Tables

Number of Products under Development for, H1 2016 7
Number of Products under Development by Therapy Area, H1 2016 8
Number of Products under Development by Indication, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Number of Products under Development by Companies, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Development by Companies, H1 2016 (Contd..1) 15
Assessment by Monotherapy/Combination Products, H1 2016 16
Number of Products by Stage and Mechanism of Action, H1 2016 17
Number of Products by Stage and Route of Administration, H1 2016 19
Number of Products by Stage and Molecule Type, H1 2016 20
Pipeline by Amgen Inc., H1 2016 21
Pipeline by LG Life Science LTD., H1 2016 23
Dormant Projects, H1 2016 47